Microfluidic Encapsulation of Exosomes Derived from Lipopolysaccharide-Treated Mesenchymal Stem Cells in Hyaluronic Acid Methacryloyl to Restore Ovarian Function in Mice.
Yifan LiHui ZhangChangjun CaiJialian MaoNing LiDanqing HuangShiyuan LiJun YangJidong ZhouHuan WangYujuan ZhuLijun DingHaixiang SunPublished in: Advanced healthcare materials (2023)
Premature ovarian failure (POF) features an upward incidence nowadays, and the human umbilical cord mesenchymal stem cells (hUC-MSCs)-derived exosomes (MSC-Exos) have shown applied values in the recovery of ovarian function. Here, a novel exosome-encapsulated microcarrier prepared by microfluidic technology for ovarian repair after chemotherapy damage is presented. The exosomes derived from lipopolysaccharide (LPS)-preconditioned hUC-MSCs are encapsulated with hyaluronic acid methacryloyl (HAMA) via microfluidic electrospray, which is named HAMA/MSC-Exos. Attributing to the biocompatibility and semipermeable property of HAMA, the encapsulated exosomes show great viability and controllable release behavior from HAMA. It is demonstrated that in situ transplantation of HAMA/MSC-Exos can rescue ovarian functions of cyclophosphamide-induced ovarian failure in mice by increasing ovarian volume, improving the number of antral follicles and restoring fertility. It is believed that the transplantation of HAMA/MSC-Exos will provide a new concept for the treatment of POF in clinical practice.
Keyphrases
- mesenchymal stem cells
- umbilical cord
- hyaluronic acid
- cell therapy
- bone marrow
- stem cells
- inflammatory response
- clinical practice
- single cell
- high throughput
- circulating tumor cells
- mass spectrometry
- endothelial cells
- radiation therapy
- oxidative stress
- type diabetes
- high dose
- immune response
- risk factors
- young adults
- diabetic rats
- lps induced
- high glucose
- label free